Geron Corporation’s Q1 2025 Financial Highlights

Geron Corporation ( (GERN) ) has released its Q1 earnings. Here is a breakdown of the information Geron Corporation presented to its investors.

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing first-in-class telomerase inhibitors for the treatment of blood cancers, with its flagship product RYTELO® (imetelstat) approved in the U.S. and EU for specific myelodysplastic syndromes.

In the first quarter of 2025, Geron Corporation reported $39.4 million in net product revenue from RYTELO, marking its first year of commercialization in the U.S. The company also received marketing authorization from the European Commission for RYTELO, with plans to launch in select EU countries in 2026.

Key financial highlights include a net loss of $19.8 million, a significant improvement from the $55.4 million loss in the same period last year. The company’s total net revenue increased to $39.6 million, driven by U.S. sales of RYTELO. Operating expenses remained stable, with a notable decrease in research and development costs due to the completion of certain clinical trials.

Strategically, Geron is advancing its Phase 3 IMpactMF clinical trial for imetelstat in relapsed/refractory myelofibrosis, with 85% enrollment achieved and interim analysis expected in the second half of 2026. The company is optimistic about the potential market opportunity for imetelstat, contingent upon positive trial outcomes and regulatory approval.

Looking ahead, Geron remains focused on maximizing the commercial potential of RYTELO in the U.S. and expanding its presence in the EU. The company believes its existing financial resources, combined with anticipated revenues, will support its operational needs for the foreseeable future.